Nutrition and AGE-ing: Focusing on Alzheimer's Disease

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Abate, Giulia ^a   Marziano, Mariagrazia ^a   Rungratanawanich, Wiramon ^a   Memo, Maurizio ^a   Uberti, Daniela ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COOKING; FATTY ACIDS; NEURODEGENERATIVE DISEASES; NUTRIENTS; SATURATED FATTY ACIDS;

ADVANCED GLYCATION END PRODUCTS; ALZHEIMER'S DISEASE; BIOLOGICAL PROCESS; CHRONIC DISABILITY; ELDERLY POPULATIONS; HARMFUL COMPOUNDS; NEURODEGENERATIVE; NUTRITIONAL PROPERTIES;

NUTRITION;

ADVANCED GLYCATION END PRODUCT; FLAVONOID; POLYPHENOL; TOXIC SUBSTANCE; VITAMIN;

AGING; ALZHEIMER DISEASE; CAUSALITY; DIET; DISEASE ASSOCIATION; EDUCATION; FOOD; FOOD PROCESSING; HUMAN; MENTAL DETERIORATION; NONHUMAN; NUTRIENT; NUTRITION; REVIEW; AGED; DISEASE COURSE; METABOLISM; NUTRITIONAL STATUS;

DISEASES; NUTRITION;

AGED; ALZHEIMER DISEASE; DIET; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NUTRITIONAL STATUS;

EID: 85010635899     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/7039816     Document Type: Review

References (99)

1. P. Sebastiani, T. T. Perls, "The genetics of extreme longevity: lessons from the new england centenarian study, " Frontiers in Genetics, vol. 3, article no. 277, 2012.
2. M. Lövdén, W. Xu, H.-X. Wang, "Lifestyle change, the prevention of cognitive decline, dementia: what is the evidence" CurrentOpinion in Psychiatry, vol. 26, no. 3, pp. 239-243, 2013.
3. T. Ahmed, N. Haboubi, "Assessment, management of nutrition in older people, its importance to health, " Clinical Interventions in Aging, vol. 5, pp. 207-216, 2010.
4. J. Reedy, S. M. Krebs-Smith, P. E. Miller, et al., "Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, cancer mortality among older adults, " The Journal of Nutrition, vol. 144, no. 6, pp. 881-889, 2014.
5. P. C. Calder, "Marine omega-3 fatty acids, inflammatory processes: effects, mechanisms, clinical relevance, " Biochimica et Biophysica Acta-Molecular, Cell Biology of Lipids, vol. 1851, no. 4, pp. 469-484, 2015.
6. C. Prasad, V. Imrhan, F. Marotta, S. Juma, P. Vijayagopal, "Lifestyle, advanced glycation end products (AGEs) burden: its relevance to healthy aging, " Aging, Disease, vol. 5, no. 3, pp. 212-217, 2014.
7. Alzheimer's Disease International, World Alzheimer Report 2015, The Global Economic Impact of Dementia, 2015.
8. K. Shoghi-Jadid, G. W. Small, E. D. Agdeppa, et al., "Localization of neurofibrillary tangles, beta-amyloid plaques in the brains of living patients with Alzheimer disease, " The American Journal of Geriatric Psychiatry, vol. 10, no. 1, pp. 24-35, 2002.
9. D. J. Selkoe, J. Hardy, "The amyloid hypothesis of Alzheimer's disease at 25 years, " EMBOMolecularMedicine, vol. 8, no. 6, pp. 595-608, 2016.
10. P. Agostinho, R. A. Cunha, C. Oliveira, "Neuroinflammation, oxidative stress, the pathogenesis of Alzheimer's disease, " Current Pharmaceutical Design, vol. 16, no. 25, pp. 2766-2778, 2010.
11. M. D. M. Haag, A. Hofman, P. J. Koudstaal, B. H. C. Stricker, M. M. B. Breteler, "Statins are associatedwith a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study, " Journal of Neurology, Neurosurgery, Psychiatry, vol. 80, no. 1, pp. 13-17, 2009.
12. H. L. Daneschvar, M. D. Aronson, G. W. Smetana, "Do statins prevent Alzheimer's disease A narrative review, " European Journal of Internal Medicine, vol. 26, no. 9, pp. 666-669, 2015.
13. S. Gillette-Guyonnet, M. Secher, B. Vellas, "Nutrition, neurodegeneration: epidemiological evidence, challenges for future research, " British Journal of Clinical Pharmacology, vol. 75, no. 3, pp. 738-755, 2013.
14. E. M. van derBeek, P. J. G. H. Kamphuis, "The potential role of nutritional components in the management of Alzheimer's Disease, " European Journal of Pharmacology, vol. 585, no. 1, pp. 197-207, 2008.
15. L. Nelson andN. Tabet, "Slowing the progression of Alzheimer's disease; what works" Ageing Research Reviews, vol. 23, pp. 193-209, 2015.
16. D. Vauzour, A. Martinsen, S. Layé, "Neuroinflammatory processes in cognitive disorders: is there a role for flavonoids, n-3 polyunsaturated fatty acids in counteracting their detrimental effects" Neurochemistry International, vol. 89, pp. 63-74, 2015.
17. C. Joffre, A. Nadjar, M. Lebbadi, F. Calon, S. Laye, "n-3 LCPUFA improves cognition: the young, the old, the sick, " Prostaglandins Leukotrienes, Essential Fatty Acids, vol. 91, no. 1-2, pp. 1-20, 2014.
18. P. C. Calder, "n-3 fatty acids, inflammation, immunity: new mechanisms to explain old actions, " Proceedings of the Nutrition Society, vol. 72, no. 3, pp. 326-336, 2013.
19. C. N. Serhan, N. Chiang, "Resolution phase lipid mediators of inflammation: agonists of resolution, " Current Opinion in Pharmacology, vol. 13, no. 4, pp. 632-640, 2013.
20. R. P. Bazinet, S. Layé, "Polyunsaturated fatty acids, theirmetabolites in brain function, disease, " Nature Reviews Neuroscience, vol. 15, no. 12, pp. 771-785, 2014.
21. Y. Freund Levi, I. Vedin, T. Cederholm, et al., "Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study, " Journal of InternalMedicine, vol. 275, no. 4, pp. 428-436, 2014.
22. P. Barberger-Gateau, C. Samieri, C. Feárt, M. Plourde, "Dietary omega 3 polyunsaturated fatty acids, Alzheimer's disease: interaction with apolipoprotein E genotype, " Current Alzheimer Research, vol. 8, no. 5, pp. 479-491, 2011.
23. P. Sebastiani, T. T. Perls, "The genetics of extreme longevity: lessons from the new england centenarian study, " Frontiers in Genetics, vol. 3, article no. 277, 2012.
24. M. Lövdén, W. Xu, H.-X. Wang, "Lifestyle change, the prevention of cognitive decline, dementia: what is the evidence" CurrentOpinion in Psychiatry, vol. 26, no. 3, pp. 239-243, 2013.
25. T. Ahmed, N. Haboubi, "Assessment, management of nutrition in older people, its importance to health, " Clinical Interventions in Aging, vol. 5, pp. 207-216, 2010.
26. J. Reedy, S. M. Krebs-Smith, P. E. Miller, et al., "Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, cancer mortality among older adults, " The Journal of Nutrition, vol. 144, no. 6, pp. 881-889, 2014.
27. P. C. Calder, "Marine omega-3 fatty acids, inflammatory processes: effects, mechanisms, clinical relevance, " Biochimica et Biophysica Acta-Molecular, Cell Biology of Lipids, vol. 1851, no. 4, pp. 469-484, 2015.
28. C. Prasad, V. Imrhan, F. Marotta, S. Juma, P. Vijayagopal, "Lifestyle, advanced glycation end products (AGEs) burden: its relevance to healthy aging, " Aging, Disease, vol. 5, no. 3, pp. 212-217, 2014.
29. Alzheimer's Disease International, World Alzheimer Report 2015, The Global Economic Impact of Dementia, 2015.
30. K. Shoghi-Jadid, G. W. Small, E. D. Agdeppa, et al., "Localization of neurofibrillary tangles, beta-amyloid plaques in the brains of living patients with Alzheimer disease, " The American Journal of Geriatric Psychiatry, vol. 10, no. 1, pp. 24-35, 2002.
31. D. J. Selkoe, J. Hardy, "The amyloid hypothesis of Alzheimer's disease at 25 years, " EMBOMolecularMedicine, vol. 8, no. 6, pp. 595-608, 2016.
32. P. Agostinho, R. A. Cunha, C. Oliveira, "Neuroinflammation, oxidative stress, the pathogenesis of Alzheimer's disease, " Current Pharmaceutical Design, vol. 16, no. 25, pp. 2766-2778, 2010.
33. M. D. M. Haag, A. Hofman, P. J. Koudstaal, B. H. C. Stricker, M. M. B. Breteler, "Statins are associatedwith a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study, " Journal of Neurology, Neurosurgery, Psychiatry, vol. 80, no. 1, pp. 13-17, 2009.
34. H. L. Daneschvar, M. D. Aronson, G. W. Smetana, "Do statins prevent Alzheimer's disease A narrative review, " European Journal of Internal Medicine, vol. 26, no. 9, pp. 666-669, 2015.
35. S. Gillette-Guyonnet, M. Secher, B. Vellas, "Nutrition, neurodegeneration: epidemiological evidence, challenges for future research, " British Journal of Clinical Pharmacology, vol. 75, no. 3, pp. 738-755, 2013.
36. E. M. van derBeek, P. J. G. H. Kamphuis, "The potential role of nutritional components in the management of Alzheimer's Disease, " European Journal of Pharmacology, vol. 585, no. 1, pp. 197-207, 2008.
37. L. Nelson andN. Tabet, "Slowing the progression of Alzheimer's disease; what works" Ageing Research Reviews, vol. 23, pp. 193-209, 2015.
38. D. Vauzour, A. Martinsen, S. Layé, "Neuroinflammatory processes in cognitive disorders: is there a role for flavonoids, n-3 polyunsaturated fatty acids in counteracting their detrimental effects" Neurochemistry International, vol. 89, pp. 63-74, 2015.
39. C. Joffre, A. Nadjar, M. Lebbadi, F. Calon, S. Laye, "n-3 LCPUFA improves cognition: the young, the old, the sick, " Prostaglandins Leukotrienes, Essential Fatty Acids, vol. 91, no. 1-2, pp. 1-20, 2014.
40. P. C. Calder, "n-3 fatty acids, inflammation, immunity: new mechanisms to explain old actions, " Proceedings of the Nutrition Society, vol. 72, no. 3, pp. 326-336, 2013.
41. C. N. Serhan, N. Chiang, "Resolution phase lipid mediators of inflammation: agonists of resolution, " Current Opinion in Pharmacology, vol. 13, no. 4, pp. 632-640, 2013.
42. R. P. Bazinet, S. Layé, "Polyunsaturated fatty acids, theirmetabolites in brain function, disease, " Nature Reviews Neuroscience, vol. 15, no. 12, pp. 771-785, 2014.
43. Y. Freund Levi, I. Vedin, T. Cederholm, et al., "Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study, " Journal of InternalMedicine, vol. 275, no. 4, pp. 428-436, 2014.
44. P. Barberger-Gateau, C. Samieri, C. Feárt, M. Plourde, "Dietary omega 3 polyunsaturated fatty acids, Alzheimer's disease: interaction with apolipoprotein E genotype, " Current Alzheimer Research, vol. 8, no. 5, pp. 479-491, 2011.
45. S. De Nicoló, L. Tarani, M. Ceccanti, et al., "Effects of olive polyphenols administration on nerve growth factor, brainderived neurotrophic factor in the mouse brain, " Nutrition, vol. 29, no. 4, pp. 681-687, 2013.
46. C. Rendeiro, A. Foley, V. C. Lau, et al., "A role for hippocampal PSA-NCAMandNMDA-NR2B receptor function in flavonoidinduced spatial memory improvements in young rats, " Neuropharmacology, vol. 79, pp. 335-344, 2014.
47. J. Bensalem, L. Servant, S. Alfos, et al., "Dietary polyphenol supplementation prevents alterations of spatial navigation in middle-aged mice, " Frontiers in Behavioral Neuroscience, vol. 10, article no. 9, 2016.
48. K. Ono, Y. Yoshiike, A. Takashima, K. Hasegawa, H. Naiki, M. Yamada, "Potent anti-amyloidogenic, fibril-destabilizing effects of polyphenols in vitro: implications for the prevention, therapeutics of Alzheimer's disease, " Journal of Neurochemistry, vol. 87, no. 1, pp. 172-181, 2003.
49. E. Younesi, "Evidence-based modeling of mode-of-action for functional ingredients influencing Alzheimer's disease through neurotrophin pathway, " Functional Foods inHealth, Disease, vol. 4, no. 8, pp. 362-369, 2014.
50. M. Afzal, A. M. Safer, M. Menon, "Green tea polyphenols, their potential role in health, disease, " Inflammopharmacology, vol. 23, no. 4, pp. 151-161, 2015.
51. J. Cheng-Chung Wei, H.-C. Huang, W.-J. Chen, C.-N. Huang, C.-H. Peng, C.-L. Lin, "Epigallocatechin gallate attenuates amyloid-induced inflammation, neurotoxicity in EOC 13. 31 microglia, "EuropeanJournal of Pharmacology, vol. 770, pp. 16-24, 2016.
52. B. B. Aggarwal, K. B. Harikumar, "Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune, neoplastic diseases, " International Journal of Biochemistry, Cell Biology, vol. 41, no. 1, pp. 40-59, 2009.
53. S. A. Frautschy, W. Hu, P. Kim, et al., "Phenolic antiinflammatory antioxidant reversal of A-induced cognitive deficits, neuropathology, " Neurobiology of Aging, vol. 22, no. 6, pp. 993-1005, 2001.
54. L. Zhang, M. Fiala, J. Cashman, et al., "Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients, " Journal of Alzheimer's Disease, vol. 10, no. 1, pp. 1-7, 2006.
55. S. S. Ambegaokar, L. Wu, K. Alamshahi, et al., "Curcumin inhibits dose-dependently, time-dependently neuroglial cell proliferation, growth, " Neuroendocrinology Letters, vol. 24, no. 6, pp. 469-473, 2003.
56. G.-Y. Kim, K.-H. Kim, S.-H. Lee, et al., "Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs, translocation of NF-B as potential targets, " Journal of Immunology, vol. 174, no. 12, pp. 8116-8124, 2005.
57. M. Garcia-Alloza, L. A. Borrelli, A. Rozkalne, B. T. Hyman, B. J. Bacskai, "Curcumin labels amyloid pathology in vivo, disrupts existing plaques, partially restores distorted neurites in an Alzheimer mouse model, " Journal of Neurochemistry, vol. 102, no. 4, pp. 1095-1104, 2007.
58. K. Ono, K. Hasegawa, H. Naiki, M. Yamada, "Curcumin has potent anti-amyloidogenic effects for Alzheimer's-amyloid fibrils in vitro, " Journal of Neuroscience Research, vol. 75, no. 6, pp. 742-750, 2004.
59. T. Goldberg, W. Cai, M. Peppa, et al., "Advanced glycoxidation end products in commonly consumed foods, " Journal of the American Dietetic Association, vol. 104, no. 8, pp. 1287-1291, 2004.
60. W. Cai, J. Uribarri, L. Zhu, et al., "Oral glycotoxins are a modifiable cause of dementia, the metabolic syndrome in mice, humans, " Proceedings of the National Academy of Sciences of theUnited States of America, vol. 111, no. 13, pp. 4940-4945, 2014.
61. O. Nedíc, S. I. S. Rattan, T. Grune, I. P. Trougakos, "Molecular effects of advanced glycation end products on cell signalling pathways, ageing, pathophysiology, " Free Radical Research, vol. 47, no. 1, pp. 28-38, 2013.
62. J. Uribarri, M. D. del Castillo, M. P. de la Maza, et al., "Dietary advanced glycation end products, their role in health, disease, " Advances in Nutrition, vol. 6, no. 4, pp. 461-473, 2015.
63. C. Matrone, M. Djelloul, G. Taglialatela, L. Perrone, "Inflammatory risk factors, pathologies promoting Alzheimer's disease progression: is RAGE the key" Histology, Histopathology, vol. 30, no. 2, pp. 125-139, 2015.
64. B.-R. Choi, W.-H. Cho, J. Kimet al., "Increasedexpressionof the receptor for advanced glycation end products in neurons, astrocytes in a triple transgenic mouse model of Alzheimer's disease, " Experimental, Molecular Medicine, vol. 46, no. 2, article e75, 2014.
65. E. C. W. van Straaten, D. Harvey, P. Scheltens, et al., "Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia, " Journal of Neurology, vol. 255, no. 9, pp. 1302-1308, 2008.
66. Z.-M. Shi, Y.-W. Han, X.-H. Hanet al., "Upstreamregulators, downstream effectors of NF-B in Alzheimer's disease, " Journal of the Neurological Sciences, vol. 366, pp. 127-134, 2016.
67. M. S. Beeri, E. Moshier, J. Schmeidler, et al., "Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals, " Mechanisms of Ageing andDevelopment, vol. 132, no. 11-12, pp. 583-587, 2011.
68. P. Salahuddin, G. Rabbani, R. H. Khan, "The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach, " Cellular, Molecular Biology Letters, vol. 19, no. 3, pp. 407-437, 2014.
69. L.-F. Lue, D. G. Walker, L. Brachova, et al., "Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism, " Experimental Neurology, vol. 171, no. 1, pp. 29-45, 2001.
70. M. O. Chaney, W. B. Stine, T. A. Kokjohn, et al., "RAGE, amyloid beta interactions: atomic force microscopy, molecular modeling, " Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1741, no. 1-2, pp. 199-205, 2005.
71. F. Liang, J. Jia, S. Wang, W. Qin, G. Liu, "Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP), the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease, " Journal of Clinical Neuroscience, vol. 20, no. 3, pp. 357-361, 2013.
72. J. Provias, B. Jeynes, "The role of the blood-brain barrier in the pathogenesis of senile plaques in Alzheimer's disease, " International Journal of Alzheimer's Disease, vol. 2014, Article ID 191863, 7 pages, 2014.
73. O. Arancio, H. P. Zhang, X. Chen, et al., "RAGE potentiates A-induced perturbation of neuronal function in transgenic mice, " The EMBO Journal, vol. 23, no. 20, pp. 4096-4105, 2004.
74. K. I. Mosher, T. Wyss-Coray, "Microglial dysfunction in brain aging, Alzheimer's disease, " Biochemical Pharmacology, vol. 88, no. 4, pp. 594-604, 2014.
75. L. Perrone, T. S. Devi, K.-I. Hosoya, T. Terasaki, L. P. Singh, "Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions, " Journal of Cellular Physiology, vol. 221, no. 1, pp. 262-272, 2009.
76. L. Perrone, O. Sbai, P. P. Nawroth, A. Bierhaus, "The complexity of sporadic Alzheimer's disease pathogenesis: the role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction, " International Journal of Alzheimer's Disease, vol. 2012, Article ID 734956, 13 pages, 2012.
77. O. Sbai, T. S. Devi, M. A. B. Melone, et al., "RAGE-TXNIP axis is required for S100B-promoted Schwann cell migration, fibronectin expression, cytokine secretion, " Journal of Cell Science, vol. 123, no. 24, pp. 4332-4339, 2010.
78. L. Buizza, G. Cenini, C. Lanni, et al., "Conformational altered p53 as an earlymarker of oxidative stress inAlzheimer's disease, " PLoS ONE, vol. 7, no. 1, Article ID e29789, 2012.
79. S. J. Webster, S. Mruthinti, W. D. Hill, J. J. Buccafusco, A. V. Terry Jr., "An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease, " NeuroMolecular Medicine, vol. 14, no. 2, pp. 119-130, 2012.
80. B. Kuhla, K. Boeck, A. Schmidt, et al., "Age-, stagedependent glyoxalase I expression, its activity in normal, Alzheimer's disease brains, " Neurobiology of Aging, vol. 28, no. 1, pp. 29-41, 2007.
81. J. Uribarri, M. Peppa, W. Cai, et al., "Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients, " Journal of the American Society of Nephrology, vol. 14, no. 3, pp. 728-731, 2003.
82. J. Uribarri, W. Cai, M. Peppa, et al., "Circulating glycotoxins, dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, aging, " Journals of Gerontology Series A: Biological Sciences, Medical Sciences, vol. 62, no. 4, pp. 427-433, 2007.
83. L. Perrone, W. B. Grant, "Observational, ecological studies of dietary advanced glycation end products in national diets andAlzheimer's disease incidence, prevalence, " Journal of Alzheimer's Disease, vol. 45, no. 3, pp. 965-979, 2015.
84. M. Ozawa, T. Ohara, T. Ninomiya, et al., "Milk, dairy consumption, risk of dementia in an elderly Japanese population: the Hisayama Study, " Journal of the American Geriatrics Society, vol. 62, no. 7, pp. 1224-1230, 2014.
85. M. Ozawa, T. Ninomiya, T. Ohara, et al., "Dietary patterns, risk of dementia in an elderly Japanese population: the Hisayama Study, " American Journal of Clinical Nutrition, vol. 97, no. 5, pp. 1076-1082, 2013.
86. N. D. Barnard, A. I. Bush, A. Ceccarelli, et al., "Dietary, lifestyle guidelines for the prevention of Alzheimer's disease, " Neurobiology of Aging, vol. 35, no. 2, pp. S74-S78, 2014.
87. A. I. Bush, "The metal theory of Alzheimer's disease, " Journal of Alzheimer's Disease, vol. 33, supplement 1, pp. S277-S281, 2013.
88. L. Letra, I. Santana, R. Seica, "Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines, " Metabolic Brain Disease, vol. 29, no. 3, pp. 563-568, 2014.
89. C. Balion, L. E. Griffith, L. Strifler, et al., "Vitamin D, cognition, dementia; a systematic review, meta-analysis, " Neurology, vol. 79, no. 13, pp. 1397-1405, 2012.
90. K. I. Erickson, A. M. Weinstein, O. L. Lopez, "Physical Activity, Brain Plasticity, Alzheimer's Disease, " Archives of Medical Research, vol. 43, no. 8, pp. 615-621, 2012.
91. A. K. Piazza-Gardner, T. J. B. Gaffud, A. E. Barry, "The impact of alcohol on Alzheimer's disease: a systematic review, " Aging, Mental Health, vol. 17, no. 2, pp. 133-146, 2013.
92. A. B. Hill, "The environment, disease: association or causation" Journal of the Royal Society ofMedicine, vol. 58, no. 5, pp. 295-300, 1965.
93. K. Sebeková, V. Somoza, "Dietary advanced glycation endproducts (AGEs), their health effects-PRO, " Molecular Nutrition, Food Research, vol. 51, no. 9, pp. 1079-1084, 2007.
94. J. Uribarri, S. Woodruff, S. Goodman, et al., "Advanced glycation end products in foods, a practical guide to their reduction in the diet, " Journal of the American Dietetic Association, vol. 110, no. 6, pp. 911-916. e12, 2010.
95. P. Pouillart, H. Mauprivez, L. Ait-Ameur, et al., "Strategy for the study of the health impact of dietary Maillard products in clinical studies: the example of the ICARE clinical study on healthy adults, " Annals of the New York Academy of Sciences, vol. 1126, pp. 173-176, 2008.
96. G. Abate, A. Delbarba, M. Marziano, et al., "Advanced Glycation End Products (AGEs) in Food: focusing on mediterranean pasta, " Journal of Nutrition & Food Sciences, vol. 5, article no. 440, 2015.
97. R. P. Dearlove, P. Greenspan, D. K. Hartle, R. B. Swanson, J. L. Hargrove, "Inhibition of protein glycation by extracts of culinary herbs, spices, " Journal ofMedicinal Food, vol. 11, no. 2, pp. 275-281, 2008.
98. L. Lv, X. Shao, H. Chen, C.-T. Ho, S. Sang, "Genistein inhibits advanced glycation end product formation by trapping methylglyoxal, " Chemical Research in Toxicology, vol. 24, no. 4, pp. 579-586, 2011.
99. I. Sadowska-Bartosz, S. Galiniak, G. Bartosz, "Kinetics of glycoxidation of bovine serum albumin by methylglyoxal, glyoxal, its prevention by various compounds, " Molecules, vol. 19, no. 4, pp. 4880-4896, 2014.